Pancreatic Cancer Therapeutics Market by Type, Product, End-Use

Description

List of Tables

[198 Pages Report] The Pancreatic Cancer Therapeutics Market size was estimated at USD 4.67 billion in 2023 and expected to reach USD 5.14 billion in 2024, at a CAGR 9.95% to reach USD 9.09 billion by 2030.

Pancreatic cancer therapeutics encompass a variety of treatment modalities used to manage and combat pancreatic cancer, known for its aggressive nature and challenging prognosis. The therapeutic landscape for this malignancy includes surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and supportive care measures that aim to relieve symptoms and improve the quality of life for patients. The need for pancreatic cancer therapeutics is driven by the increasing prevalence of the disease, attributed to factors such as aging populations, lifestyle-related risk factors, and genetic predispositions. Additionally, supportive government policies to expand access to affordable pancreatic cancer treatment have extended the scope and reach of the therapeutic options for patients. However, the complex reimbursement landscape and the inability of clinical trials to provide beneficial and credible results pose concerns about the accuracy and efficacy of the therapies. Moreover, there has been some significant progress in understanding the biology of the disease, resulting in the development of targeted therapeutics and personalized medicine approaches. These treatments are designed to interfere with specific pathways or mechanisms that promote the growth and spread of pancreatic cancer cells.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.67 billion
Estimated Year [2024]	USD 5.14 billion
Forecast Year [2030]	USD 9.09 billion
CAGR (%)	9.95%

Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer

Pancreatic neuroendocrine tumors (NETs), also called endocrine pancreatic cancer or islet cell tumors, are a type of cancer associated with the rapid and abnormal growth of endocrine cells, called islet cells, in the pancreas. Treatment for this type of cancer usually involves surgery to remove the tumor cells or the major parts of the body and tail of the pancreas. Furthermore, for tumors that cannot be removed by surgery, treatment may include a combination of chemotherapy or hormone therapy. Exocrine pancreatic cancer, or adenocarcinoma, refers to cancers that form in the tissue of the pancreas, within the ducts that carry pancreatic juices and aid digestion. However, compared to endocrine pancreatic cancers, exocrine pancreatic cancers advance rapidly.

Product: Expanding number of approvals for chemotherapy treatment options

Chemotherapy remains an essential pillar in the treatment of pancreatic cancer, involving systemic drug administration to impede cancer cell proliferation. These cytotoxic medications can be taken orally or injected, and their inability to distinguish between malignant and normal cells results in side effects. However, chemotherapy is a critical component of the therapeutic regimen, employed alongside other strategies to enhance patient outcomes. Gene therapy represents a cutting-edge technique, delivering new genetic material into patients' cells to rectify defective genes responsible for cancer growth or to introduce genes that trigger an immune response against tumor cells. Presently, gene therapy for pancreatic cancer is largely exploratory and confined to clinical research, holding the promise of more precise, individualized treatments in the future. Immunotherapy is a rapidly evolving field that leverages the body's immune defenses against cancer. Pancreatic cancer treatments, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies, are scrutinized for their ability to target cancer cells effectively. The efficacy of immunotherapy in pancreatic cancer varies. However, ongoing investigations are assessing its potential, especially for patients with specific genetic markers. Radiation therapy, a technique employing high-energy particles to eradicate cancer cells, can serve as a solitary treatment or in combination with surgical interventions to manage pancreatic cancer. Technological advancements such as stereotactic body radiation therapy (SBRT) enhance the accuracy of radiation delivery, minimizing collateral damage to healthy tissues. Surgery is the preferred approach for early-stage pancreatic cancer, aiming to excise the tumor completely. Various surgical techniques, such as the Whipple procedure or distal pancreatectomy, are determined by the tumor's pancreatic location. The viability of surgery depends on the cancer's stage and the patient's health status, and it is typically augmented by chemotherapy and radiation to optimize results. Targeted therapy offers a more nuanced attack on cancer by pinpointing and inhibiting specific molecular abnormalities or pathways involved in tumor progression.

End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment

Clinics provide personalized care with a focus on chemotherapy and patient follow-up. However, hospitals are at the core of providing comprehensive care for pancreatic cancer patients as they provide advanced surgery procedures and post-operative care facilities. They are pivotal in conducting major surgical procedures such as Whipple procedures, which are essential for treating operable pancreatic cancer. Research and academic institutions collaborate with biopharmaceutical companies to develop and test new treatments. Furthermore, they provide a foundation for evidence-based practice and contribute to the overall understanding of disease management, which can translate into improved drugs and care strategies.

Regional Insights

The Americas region, particularly the United States and Canada, is characterized by the presence of a robust clinical pipeline, high healthcare expenditure, and several major pharmaceutical companies. Food and Drug Administration (FDA) has approved designations such as Fast Track, Breakthrough Therapy, and Orphan Drug to several pancreatic cancer drugs, which accelerates the regulatory approval process. European nations such as Germany, France, and the United Kingdom are characterized by the presence of heightened healthcare spending, advanced healthcare facilities, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a pivotal role in endorsing new therapeutic options, positively impacting market growth. Strong research collaborations between private and public entities drive innovation in cancer therapeutic research. In APAC countries such as China, Japan, India, and South Korea, there is a growing patient population and increasing awareness regarding cancer diseases, driving the need for therapeutic options. The increase in local generic drug production in countries such as India contributes to regional market dynamics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pancreatic Cancer Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pancreatic Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Endocrine Pancreatic Cancer
- Exocrine Pancreatic Cancer

Product
- Chemotherapy
- Gene Therapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy

End-Use
- Cancer Centers/Clinics
- Hospitals
- Research Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pancreatic Cancer Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pancreatic Cancer Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Pancreatic Cancer Therapeutics Market?

4. What is the market share of the leading vendors in the Pancreatic Cancer Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Pancreatic Cancer Therapeutics Market?

Product Code: MRR-4342CA32667F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
  - 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
- 5.1.2. Restraints
  - 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
- 5.1.3. Opportunities
  - 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
  - 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
- 5.1.4. Challenges
  - 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
5.2. Market Segmentation Analysis
- 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
- 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
- 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
5.3. Market Trend Analysis
- 5.3.1. Advancements in pancreatic cancer therapeutics in Americas region due to strong presence of key players and supportive regulatory landscape
- 5.3.2. Collaborative R&D activities by cancer research organization and improved support for clinical trials of novel therapies to elevate the advancements in pancreatic cancer therapeutics in the Asia-Pacific
- 5.3.3. Concerted efforts of researchers, funding agencies, and regulatory bodies catalyzing to delivering novel pancreatic cancer therapeutic solutions across EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Pancreatic Cancer Therapeutics Market, by Type

6.1. Introduction
6.2. Endocrine Pancreatic Cancer
6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

7.1. Introduction
7.2. Chemotherapy
7.3. Gene Therapy
7.4. Immunotherapy
7.5. Radiation Therapy
7.6. Surgery
7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

8.1. Introduction
8.2. Cancer Centers/Clinics
8.3. Hospitals
8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
- 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
- 12.3.3. PanCAN Announces New & Advanced Research Investment
- 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
- 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
- 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
- 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
- 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
- 12.3.9. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
- 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
- 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
- 12.3.12. Leap Therapeutics Acquires Flame Biosciences
- 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
- 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
- 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio